coronaviru
diseas
novel
envelop
rna
betacoronaviru
emerg
wuhan
china
decemb
rapidli
becom
worldwid
pandem
affect
hundr
thousand
peopl
caus
death
estim
infect
case
common
clinic
present
respiratori
symptom
fever
short
breath
cough
associ
radiograph
find
consist
pneumonia
preval
abnorm
liver
test
initi
present
still
undetermin
current
approv
therapi
support
care
enrol
clinic
trial
use
offlabel
therapi
vitamin
c
hydroxychloroquin
without
support
random
clinic
trial
support
efficaci
report
first
case
present
acut
nonicter
hepat
woman
present
emerg
depart
chief
concern
dark
urin
enter
facil
isol
surgic
mask
place
face
per
protocol
deni
cough
sore
throat
short
breath
diarrhea
nausea
vomit
abdomin
pain
live
alon
deni
sick
contact
medic
histori
wellcontrol
human
immunodefici
viru
viral
load
undetect
hypertens
hyperlipidemia
grave
diseas
left
facial
paralysi
secondari
previou
actinomycosi
infect
deni
recent
intak
acetaminophen
antibiot
outpati
medic
includ
clonidin
fish
oil
levothyroxin
amlodipin
propranolol
hydrochlorothiazid
mvi
genvoya
elvitegravir
cobicistat
emtricitabin
tenofovir
alafenamid
recent
outpati
liver
chemistri
normal
admit
concern
rise
liver
test
patient
human
immunodefici
viru
diseas
present
temperatur
cutan
manifest
lung
examin
normal
jaundic
right
upper
quadrant
tender
hepatomegali
splenomegali
laboratori
result
follow
white
blood
cell
count
gl
platelet
gl
serum
bilirubin
admiss
day
hour
present
emerg
depart
develop
fever
spo
room
air
chest
xray
show
bilater
interstiti
opac
nasopharyng
sampl
taken
sarscov
pcr
test
posit
patient
place
l
oxygen
admiss
day
start
cours
hydroxychloroquin
mg
bid
well
discharg
home
hospit
day
serum
bilirubin
mgdl
ast
iul
alt
iul
alkalin
phosphatas
iul
serum
albumin
gdl
inr
figur
outpati
medic
includ
human
immunodefici
viru
treatment
continu
throughout
entir
admiss
infect
typic
present
respiratori
symptom
fever
sore
throat
cough
short
breath
highvolum
center
liver
test
abnorm
note
follow
diagnosi
report
first
case
infect
present
acut
nonicter
hepat
develop
fever
respiratori
symptom
patient
stabl
outpati
medic
regimen
normal
outpati
liver
test
admiss
initi
present
typic
evalu
acut
hepat
workup
neg
hour
admiss
develop
respiratori
symptom
subsequ
diagnos
treat
hydroxychloroquin
symptom
improv
liver
chemistri
caus
acut
nonicter
hepat
rule
seem
highli
like
acut
hepat
caus
infect
current
standard
care
treatment
infect
current
therapi
includ
implement
infect
control
measur
symptomat
treatment
support
care
includ
supplement
oxygen
mechan
ventil
appropri
current
approv
therapi
treat
infect
clinic
trial
ongo
evalu
antivir
therapi
immunemodul
therapi
antimalari
antiinflammatori
medic
hydroxychloroquin
wide
use
treat
infect
without
avail
data
random
clinic
trial
inform
clinic
guidanc
use
dose
durat
hydroxychloroquin
prophylaxi
treatment
infect
hydroxychloroquin
shown
vitro
activ
sarscov
singl
nonrandom
studi
patient
franc
suggest
hydroxychloroquin
lower
coronaviru
level
blood
compar
untreat
control
shorten
recoveri
time
six
patient
receiv
hydroxychloroquin
also
receiv
azithromycin
wherea
none
control
receiv
azithromycin
random
studi
china
report
hydroxychloroquin
show
benefit
treat
infect
hydroxychloroquin
current
investig
clinic
trial
preexposur
postexposur
prophylaxi
infect
treatment
patient
mild
moder
sever
review
limit
literatur
date
case
appear
first
report
case
infect
present
acut
hepat
develop
respiratori
symptom
clinic
awar
era
infect
acut
nonicter
hepat
may
viru
initi
present
develop
respiratori
symptom
patient
risk
factor
present
acut
hepat
isol
undergo
test
observ
studi
need
determin
frequenc
present
mildtomoder
liver
test
abnorm
evolv
pandem
guarantor
articl
david
bernstein
md
specif
author
contribut
author
contribut
write
case
report
financi
support
none
report
potenti
compet
interest
none
report
